Results 41 to 50 of about 13,452 (195)

Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway

Frontiers in Oncology, 2018
Radiation-induced chromosomal aberrations represent an early marker of late effects, including cell killing and transformation. The measurement of cytogenetic damage in tissues, generally in blood lymphocytes, from patients treated with radiotherapy has ...
Marco Durante, Silvia C. Formenti
doaj   +1 more source

Tissue Factor‐Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer

Advancement of science, 2020
Anaplastic thyroid cancer (ATC) is the most aggressive subtype of thyroid cancers with a dismal prognosis. It is aimed to explore a new biomarker and devise a marker‐dependent theranostic pair for ATC.
Weijun Wei, Qiufang Liu, Dawei Jiang, Haitao Zhao, C. Kutyreff, J. Engle, Jianju Liu, W. Cai   +7 more
semanticscholar   +1 more source

CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab

Advanced Science, 2021
Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt′s lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional ...
Lei Kang, Cuicui Li, Zachary T. Rosenkrans, Nan Huo, Zhao Chen, Emily B. Ehlerding, Yan Huo, Carolina A. Ferreira, Todd E. Barnhart, Jonathan W. Engle, Rongfu Wang, Dawei Jiang, Xiaojie Xu, Weibo Cai   +13 more
doaj   +1 more source

Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model

International Journal of Molecular Sciences, 2020
Immunotherapy has changed the oncology landscape during the last decade and become standard of care for several cancers. The combinations of immunotherapy with other treatment modalities are also being investigated.
R. Jiao, K. Allen, M. Malo, D. Rickles, E. Dadachova   +4 more
semanticscholar   +1 more source

Near-Infrared Light-Responsive Nitric Oxide Delivery Platform for Enhanced Radioimmunotherapy

Nano-Micro Letters, 2020
Ag2S NO delivery platforms maximize radiotherapy effects remarkably to inhibit the tumor growth. Immunosuppressive tumor microenvironment was improved by Ag2S NO delivery system, significantly enhancing the anti-PD-L1 immune checkpoint blockade therapy ...
Xuanfang Zhou, Z. Meng, Jialin She, Yaojia Zhang, Xuan Yi, Hailin Zhou, Jing Zhong, Z. Dong, Xiao Han, Muchao Chen, Qin Fan, Kai Yang, Chao Wang   +12 more
semanticscholar   +1 more source

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model

Pharmaceuticals, 2022
In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of the humanized anti-CAIX antibody (hG250) labeled with either the α-emitter actinium-225 (225Ac) or the β--emitter lutetium-177 (177Lu) in mice.
Robin I. J. Merkx, Mark Rijpkema, Gerben M. Franssen, Annemarie Kip, Bart Smeets, Alfred Morgenstern, Frank Bruchertseifer, Eddie Yan, Michael P. Wheatcroft, Egbert Oosterwijk, Peter F. A. Mulders, Sandra Heskamp   +11 more
doaj   +1 more source

Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides

Pharmaceuticals, 2022
As the third leading cause of cancer death worldwide, hepatocellular carcinoma (HCC) is characterized by late detection, difficult diagnosis and treatment, rapid progression, and poor prognosis.
Ruiqi Liu, Hong Li, Yihua Qiu, Hongguang Liu, Zhen Cheng   +4 more
doaj   +1 more source

Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial

Pharmaceuticals, 2015
The first-in-human phase 1 clinical radioimmunotherapy (RIT) trial with 212Pb-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)-cyclododecane-trastuzumab (212Pb-TCMC-trastuzumab) was completed in October 2014 as a joint effort at the University of ...
Diane E. Milenic, Kwamena E. Baidoo, Martin W. Brechbiel   +2 more
doaj   +1 more source

Improved Quantification of ¹⁸F-FDG PET during ¹³¹I-Rituximab Therapy on Mouse Lymphoma Models after ¹³¹I Prompt Emission Correction

Diagnostics, 2019
18F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to 131I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from 131I, particularly in animal PET imaging.
Young Sub Lee, Hee-Joung Kim, Jin Su Kim   +2 more
doaj   +1 more source

Therapeutic dendritic cell vaccines engineered with antigen‐biomineralized Bi2S3 nanoparticles for personalized tumor radioimmunotherapy

Aggregate, 2022
Therapeutic vaccines, an exciting development in cancer immunotherapy, share the goal of priming of personalized antigen‐specific T‐cell response by precise antigen presentation of dendritic cells (DCs), but major obstacles include insufficient antigen ...
Huan Yu, Haoxiang Guo, He Zu, Heng Ding, Subin Lin, Yangyun Wang, Leshuai W Zhang, Yong Wang   +7 more
doaj   +1 more source